Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score

ABSTRACT

Objective/Background: Progesterone-receptor negativity [PR-] is predictive of adverse outcomes in estrogen receptor-positive [ER+] breast cancer. The Oncotype DX assay provides risk stratification for hormone receptor-positive [HR+] invasive breast cancer; however, the association of PR status and Oncotype DX recurrence scores [RSs] is less clear